Advances in immunocheckpoint blockades in the treatment of non-small cell lung cancer
10.3969/j.issn.1000-8179.2015.18.815
- VernacularTitle:非小细胞肺癌免疫检查点阻断剂治疗进展
- Author:
Xiangjiao MENG
;
Ligang XING
;
Jinming YU
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
immunocheckpoint blockades;
treatment
- From:
Chinese Journal of Clinical Oncology
2015;(18):887-890
- CountryChina
- Language:Chinese
-
Abstract:
In China, most patients with non-small cell lung cancer (NSCLC) were diagnosed with advanced or metastatic disease on first admission. These patients were treated by chemotherapy, radiotherapy, or targeted therapy. However, the 5-year overall survival rate is still low. Immunocheckpoint blockades adjust the immune function, dispatch immune escape, enhance T cell activation, and kill tumor cells. Immunocheckpoint blockade becomes one of the important methods of anti-tumor treatments. This approach may also change the model of NSCLC treatment because of its promising anti-tumor activity. This review summarizes the clinical trials on immu-nocheckpoint blockades in NSCLC and the possibility of combining this technique with other treatments.
